The annual meeting of the Group was held on October 14, bringing together several representatives from the 15 hospital centers that are members of the Group, including those serving on its Board of Directors, Scientific Committee and Operations Committee.
This meeting was an opportunity for the founding couple to highlight that 79 studies have been selected by the Scientific Committee, with nearly 1,200 patients recruited. They also emphasized the important milestone of reaching 15 member institutions across Quebec and Ontario, as well as over 1,000 participants in the metastatic breast cancer registry.
Mr. Sirois also thanked many supporting partners in attendance, including Amgen, Astellas, AstraZeneca, BMS, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, Lilly, Knight, Novartis, Merck, Pfizer, Roche, Seagen, as well as Breast Cancer Canada, the Canadian Cancer Society, the MSSS, and Sardo.
Ms. McPeak recalled the importance of the work carried out together by the Consortium to increase access and participation in research that cares across the province.
